Skip to content

Central Corneal Swelling With Silicone Hydrogel Materials

Daily Wear Central Corneal Swelling With Etafilcon A and 2 Silicone Hydrogel Materials

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02328937
Enrollment
41
Registered
2014-12-31
Start date
2014-11-30
Completion date
2015-04-30
Last updated
2018-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal Swelling

Brief summary

This is a prospective, single site, unmasked, cross-over study with three silicone hydrogel contact lenses comparing central corneal swelling.

Interventions

DEVICEetafilcon A

spherical hydrophilic soft contact lens worn in a daily wear modality

DEVICEcomfilcon A

Sponsors

Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. The participant must be at leat 18 years old or older and no greater than 65 years old. Children younger than18 will likely no be able to come back and forth to the clinic during the typical work week as outlined in the above (due to school schedules) and thus not be able to adhere to the protocol. 2. The participant must be a current soft contact lens wearer who routinely wears lenses at least 6-8 hours per day and at least 4 days per week for at least the past 3 months. 3. Refraction suitable for spherical soft contact lens powers between -1.00 and -6.00 D the participant must be correctable to 20/30 or better at distance with both eyes with dispensed contact lenses. 4. The participant must be free of any active anterior segment disorders that would preclude safe contact lens wear. Active anterior segment disorders and evidence of central microbial keratitis are not allowed. However, evidence of past CLPU will be allowed so long as no more than 3 such scars are detected bilaterally. Evidence of more than 3 CLPU-like scars places excessive risk on the participant for subsequent CIE. 5. The participant must be correctable to 20/25 or better in each eye with spectacles. Amblyopia will be excluded. 6. Flat and steep corneal curvatures from keratometry readings must be between 39.00 and 48.50 D, respectively. Corneal curvatures outside this range may be indicative of a disease state, and the participants are not expected to comfortably wear the study lenses. 7. The participant must own or agree to purchase a pair of spectacles that can be worn when lenses are removed, during the washout periods, or in case of ocular discomfort or emergency.

Exclusion criteria

1. The participant has worn rigid gas permeable contact lenses within the last 30 days or PMMA lenses within the past 12 months. These lenses can transiently alter the corneal shape and influence the fitting of soft contact lenses or alter endothelial cell morphology. 2. The participant has an immunocompromising disease or any other systemic disease that in the investigator's opinion will affect ocular health or increase risk during daily contact lens wear. 3. The participant is taking any medication that in the investigator's opinion will affect ocular physiology or study participation. 4. The participant has an ocular disease or condition such as aphakia, clinically significant corneal dystrophies, corneal edema, external ocular infection, iritis, or had any anterior segment surgery. 5. The participant is taking any ocular medications. If a participant was previous taking any ocular medications, the medications must have been discontinued at least 2 weeks prior to enrollment. 6. The participant must have less than or equal to grade 2 on any of the slit lamp observations of: upper tarsal papilla, corneal staining, corneal neovascularization, conjunctival injection, and lid erythema or scales. 7. The participant is currently pregnant or lactating. Participant who become pregnant during the study will be discontinued. 8. An employee or member of the UHCMC Eye Institute or a family member of any study personnel.

Design outcomes

Primary

MeasureTime frameDescription
Central Corneal Swelling6-8 Hours Post lens insertionCorneal swelling measurements were taken in the right eye during slit lamp evaluations, 6-8 hours post lens insertion. The average corneal swelling per lens was reported.

Secondary

MeasureTime frameDescription
Limbal Redness6-8 hours post lens insertionLimbal redness was assessed in both eyes using a slit lamp, 6-8 hours post lens insertion. Redness was assessed in 4 regions of the eye (nasal, temporal, inferior and superior) and was graded with a 5-point scale (i.e. Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe). For each region (nasal, temporal, inferior and superior) the average grade was calculated by lens. The Total Grade was then calculated by summing all the average grade for each region. The regional average grade ranges from 0 to 4. The total Grade ranges from 0 to 16.

Countries

United States

Participant flow

Pre-assignment details

A total of 41 subjects were enrolled in this study. Of the enrolled subjects 3 did not meet the eligibility criteria and 38 subjects were dispensed a study lens. Of the dispensed subjects 2 were discontinued while 36 completed all study visits.

Participants by arm

ArmCount
Overall
All subjects that were dispensed at least one study lens.
38
Total38

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003FG004FG005
Period 1Lost to Follow-up000100
Period 2Adverse Event001000

Baseline characteristics

CharacteristicOverall
Age, Continuous32.9 years
STANDARD_DEVIATION 8.71
Race/Ethnicity, Customized
Asian
9 participants
Race/Ethnicity, Customized
Black or African American
10 participants
Race/Ethnicity, Customized
White
19 participants
Region of Enrollment
United States
38 participants
Sex: Female, Male
Female
33 Participants
Sex: Female, Male
Male
5 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
0 / 370 / 380 / 36
serious
Total, serious adverse events
0 / 370 / 380 / 36

Outcome results

Primary

Central Corneal Swelling

Corneal swelling measurements were taken in the right eye during slit lamp evaluations, 6-8 hours post lens insertion. The average corneal swelling per lens was reported.

Time frame: 6-8 Hours Post lens insertion

Population: All subjects that were dispensed at least one study lens throughout the duration of the study.

ArmMeasureValue (MEAN)Dispersion
Etafilcon ACentral Corneal Swelling542.2 umStandard Deviation 31.28
Lotrafilcon BCentral Corneal Swelling542.4 umStandard Deviation 30.69
Comfilcon ACentral Corneal Swelling544.3 umStandard Deviation 28.3
Secondary

Limbal Redness

Limbal redness was assessed in both eyes using a slit lamp, 6-8 hours post lens insertion. Redness was assessed in 4 regions of the eye (nasal, temporal, inferior and superior) and was graded with a 5-point scale (i.e. Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe). For each region (nasal, temporal, inferior and superior) the average grade was calculated by lens. The Total Grade was then calculated by summing all the average grade for each region. The regional average grade ranges from 0 to 4. The total Grade ranges from 0 to 16.

Time frame: 6-8 hours post lens insertion

Population: All subjects that were dispensed at least one study lens throughout the duration of this study.

ArmMeasureValue (MEAN)Dispersion
Etafilcon ALimbal Redness6.46 units on a scaleStandard Deviation 1.233
Lotrafilcon BLimbal Redness6.24 units on a scaleStandard Deviation 1.177
Comfilcon ALimbal Redness6.14 units on a scaleStandard Deviation 0.977

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026